Ziprasidone: A new atypical antipsychotic

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 6, 2001, Pages 1033-1042

  Keck P E , Jr ^a   McElroy, S L ^a   Arnold, L M ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Antipsychotic; Bipolar disorder; Schizoaffective disorder; Schizophrenia; Ziprasidone

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; CARBAMAZEPINE; CIMETIDINE; CLOZAPINE; DEXTROMETHORPHAN; DOPAMINE 2 RECEPTOR; ETHINYLESTRADIOL; HALOPERIDOL; IMIPRAMINE; KETOCONAZOLE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; ORAL CONTRACEPTIVE AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN; SEROTONIN 2 RECEPTOR; ZIPRASIDONE;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; HUMAN; MALE; MANIC DEPRESSIVE PSYCHOSIS; MEDICAL LITERATURE; NAUSEA; NEUROENDOCRINE SYSTEM; NEUROTOXICITY; ORTHOSTATIC HYPOTENSION; PSYCHOSIS; PUBLICATION; RANDOMIZED CONTROLLED TRIAL; RECEPTOR AFFINITY; SIDE EFFECT; SOMNOLENCE; SYMPTOM; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLINICAL TRIALS; DIBENZOTHIAZEPINES; DOPAMINE ANTAGONISTS; DRUG INTERACTIONS; GUIDELINES; HUMANS; PIPERAZINES; PIRENZEPINE; RISPERIDONE; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS; THIAZOLES; TIME FACTORS; TOURETTE SYNDROME;

EID: 0034871075     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.6.1033     Document Type: Article

References (51)

1. The new antipsychotics and their therapeutic potential
2. Treatment of schizophrenia
3. The deficit syndrome
4. What makes a neuroleptic atypical?
5. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison versus chlorpromazine/benztropine
6. Pharmacologic treatment of schizoaffective disorder
7. The new generation of antipsychotics: How atypical are they?
8. Ziprasidone (CP 88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity
9. Status report: Ziprasidone
10. Ziprasidone: A novel antipsychotic with unique pharmacology and therapeutic potential
11. Role of serotonin in the action of atypical antipsychotic drugs
12. Schizoaffective disorder - Role of atypical antipsychotics
13. 2 receptors by the novel neuroleptic (CP-88p59-01): A study using positron emission tomography and 11C-raclopride
14. Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone
15. Behavioral pharmacology of serotonin receptor subtypes: Hypotheses for clinical applications of selective serotonin ligands
16. 5-HT1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex
17. Risperidone: Regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain
18. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens
19. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from the prefrontal cortex, nucleus accumbens, and striatum of the rat: An in vivo microdialysis study
20. Cortical maldevelopment, antipsychotic drugs and schizophrenia
21. A pharmacological profile of WAY-100635, a potent and selective 5-HT1A receptor antagonist
22. Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: Inhibition of doral raphe cell firing and the role of 5-HT1A receptor activation
23. Neurobiological mechanisms involved in antidepressant therapies
24. 1A receptor system: Possible implications for schizophrenic negative symptoms
25. Therapeutic benefits of ziprasidone: An update of clinical trials experience
26. The pharmacokinetics (PK) of CP-88, 059 (CP) in healthy male volunteers following oral (PO) and intravenous (IV) administration
27. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function
28. Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers
29. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans
30. The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function
31. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions
32. Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers
33. Ziprasidone and the pharmacokinetics of a combined oral contraceptive
34. Ziprasidone and the cytochrome P450 2D6 in healthy extensive metabolisers
35. The effects of ketoconazole on ziprasidone pharmacokinetics: A placebo-controlled crossover study in healthy volunteers
36. The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers
37. The effects of ziprasidone on steady-state lithium levels and renal clearance of lithium
38. Pharmacokinetics of intramuscular ziprasidone in healthy volunteers: Results from two controlled studies
39. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder
40. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 4-week placebo-controlled trial
41. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial
42. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: Results from two double-blind, placebo-controlled, multicenter studies
43. Controlled treatment of acute mania with ziprasidone
44. Ziprasidone treatment of children and adolescents with Tourette's Syndrome: A pilot study
45. Intramuscular ziprasidone, 2 mg versus 10 mg in the short-term management of agitated psychotic patients
46. A comparison of rapid-acting, intramuscular (IM) ziprasidone 2 mg and 20 mg in patients with psychosis and acute agitation
47. Long-term efficacy of oral ziprasidone in schizophrenia: Results of three controlled trials
48. Cardiovascular safety profile of ziprasidone: Review of clinical development data
49. Insulin resistance in olanzapine- and ziprasidone-treated patients: Interim results of a double-blind controlled 6-week trial